Compare LPG & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPG | TBPH |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2014 | N/A |
| Metric | LPG | TBPH |
|---|---|---|
| Price | $29.40 | $18.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $35.00 | $27.80 |
| AVG Volume (30 Days) | ★ 530.3K | 376.6K |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.23 | 0.58 |
| Revenue | ★ $359,008,462.00 | $80,327,000.00 |
| Revenue This Year | $29.52 | $70.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $13.26 | $32.64 |
| Revenue Growth | N/A | ★ 27.12 |
| 52 Week Low | $16.66 | $7.90 |
| 52 Week High | $32.79 | $21.03 |
| Indicator | LPG | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 65.23 | 46.33 |
| Support Level | $27.13 | $18.83 |
| Resistance Level | $28.88 | $21.03 |
| Average True Range (ATR) | 0.91 | 0.83 |
| MACD | 0.07 | -0.18 |
| Stochastic Oscillator | 72.33 | 22.14 |
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).